KBC Group
LEGN icon

KBC Group’s Legend Biotech LEGN Stock Holding History

KBC Group’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$176K Buy
8,867
+477
+6% +$10.2K ﹤0.01% 1071
2026
Q2 		$242K Buy
8,390
+778
+10% +$21K ﹤0.01% 974
2026
Q1 		$138K Sell
7,612
-11,902
-61% -$227K ﹤0.01% 1131
2025
Q4 		$424K Hold
19,514
– – ﹤0.01% 739
2025
Q3 		$636K Buy
19,514
+2,431
+14% +$89.8K ﹤0.01% 693
2025
Q2 		$606K Sell
17,083
-9,965
-37% -$323K ﹤0.01% 690
2025
Q1 		$918K Buy
27,048
+13,904
+106% +$499K ﹤0.01% 674
2024
Q4 		$428K Hold
13,144
– – ﹤0.01% 840
2024
Q3 		$641K Hold
13,144
– – ﹤0.01% 703
2024
Q2 		$582K Hold
13,144
– – ﹤0.01% 708
2024
Q1 		$737K Sell
13,144
-2,787
-17% -$168K ﹤0.01% 697
2023
Q4 		$959K Buy
15,931
+522
+3% +$33.1K ﹤0.01% 695
2023
Q3 		$1.04M Sell
15,409
-942
-6% -$65.4K ﹤0.01% 677
2023
Q2 		$1.13M Sell
16,351
-1,000
-6% -$65.3K ﹤0.01% 684
2023
Q1 		$837K Sell
17,351
-1,200
-6% -$58.7K ﹤0.01% 732
2022
Q4 		$926K Sell
18,551
-2,108
-10% -$102K ﹤0.01% 698
2022
Q3 		$843K Sell
20,659
-1,309
-6% -$61.4K ﹤0.01% 691
2022
Q2 		$1.21M Sell
21,968
-10,897
-33% -$460K 0.01% 635
2022
Q1 		$1.19M Buy
32,865
+7,035
+27% +$278K ﹤0.01% 673
2021
Q4 		$1.2M Buy
25,830
+5,702
+28% +$289K ﹤0.01% 692
2021
Q3 		$1.02M Sell
20,128
-7,126
-26% -$297K ﹤0.01% 757
2021
Q2 		$1.12M Hold
27,254
– – ﹤0.01% 755
2021
Q1 		$791K Buy
27,254
+5,385
+25% +$147K ﹤0.01% 789
2020
Q4 		$616K Sell
21,869
-45,297
-67% -$1.3M ﹤0.01% 825
2020
Q3 		$2.07M Buy
+67,166
New +$2.26M 0.01% 584

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Triata Capital
Triata Capital Hong Kong $531M AUM 34.32% 1-Year Est. Return
Matthews International Capital Management
Matthews International Capital Management San Francisco, California $241M AUM 42.66% 1-Year Est. Return
Davern Capital Partners
Davern Capital Partners Ny, New York $514M AUM 16.9% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

KBC Group's LEGN Position: Q3 2026 in Review

KBC Group increased its Legend Biotech (LEGN) stake by 5.7% in Q3 2026, buying an estimated $10.2K and bringing the position to 8,867 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

KBC Group first reported a position in LEGN in Q3 2020 and has held it in 25 quarters since. The position peaked at $2.07M in Q3 2020. 144 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.

  • KBC Group held 8,867 shares of Legend Biotech worth $176K as of Q3 2026.
  • KBC Group bought 477 Legend Biotech shares in Q3 2026, an estimated $10.2K.
  • Legend Biotech made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1071 holding.
  • KBC Group first reported a position in Legend Biotech in Q3 2020 and has held it in 25 quarters since.
  • KBC Group's Legend Biotech position peaked at $2.07M in Q3 2020.
  • 144 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.